What we do
The EIF in 2020
Coronavirus: The EIB Group’s initiatives to address its economic consequences
Pan-European Guarantee Fund – EGF
Institutional investors
Equity products
AI Co-Investment Facility
Climate & Infrastructure Funds
Technology Transfer
European Angels Fund (EAF) - Co-investments with Business Angels
Venture capital
The Social Impact Accelerator (SIA)
Lower mid-market
Mezzanine Facility for Growth
EFSI Equity instrument
Single EU Equity Financial Instrument
COSME - Equity Facility for Growth
InnovFin Equity
Private equity secondary market transactions
EIF-NPI Equity Platform
ESCALAR Programme
Debt products
New ESIF ERDF Guarantee Fund initiative in Greece
EFSI Private Credit Programme
AGRI Guarantee Facility
AGRI Italy Platform Uncapped Guarantee Instrument
Credit enhancement
Cultural and Creative Sectors Guarantee Facility (CCS GF)
ENSI - Securitisation Initiative
Erasmus+ Master Loan Guarantee Facility
Skills & Education Guarantee Pilot
EREM debt products
Single EU Debt Financial Instrument
Documentary Finance Facility – Bulgaria
The SME Initiative
The SME Initiative Bulgaria
The SME Initiative Finland
The SME Initiative Italy
The SME Initiative Malta
The SME Initiative Romania
The SME Initiative Spain
Inclusive finance
EaSI Financial Instruments
EaSI Capacity Building Investments Window
EaSI Guarantee Instrument
EaSI Funded Instrument
European Progress Microfinance Facility
Entrepreneurs supported through Progress Microfinance
European Fund for Strategic Investments (EFSI)
How does EIF contribute to EFSI
How to apply for EFSI financing
Regional Development - Country and sector-specific initiatives
Fons d’Inversió en Tecnologia Avançada (FITA) Catalonia
Dutch Future Fund (DFF)
Dutch Alternative Credit Instrument (DACI)
PORTUGAL BLUE: a new initiative for blue economy investments
JEREMIE Greece Reflows – Business Angels’ Co-Investment Equity Instrument
German Corona Matching Facility (CMF)
Portugal Growth programme
Croatian Growth Investment Programme (CROGIP)
AGRI Italy Platform Uncapped Guarantee Instrument
ALTER’NA – ESIF EARFD Nouvelle-Aquitaine
Baltic Innovation Fund 1 (BIF 1)
Baltic Innovation Fund 2 (BIF 2)
Central Europe Fund of Funds (CEFoF)
Croatian Venture Capital Initiative (CVCi FoF)
Competitiveness Fund-of-Funds for SMEs in Romania
The Cyprus Entrepreneurship Fund (CYPEF)
Deep and Comprehensive Free Trade Area Initiative East Guarantee Facility (DCFTA)
Dutch Growth Co-Investment Programme
Dutch Venture Initiative (DVI-II)
ESIF Fund-of-Funds Greece
EAFRD FoF Portugal
EAFRD FoF Romania
The ERP-EIF Facility
ERP-EIF Co-Investment Growth Facility
The LfA-EIF Facilities
The German Future Fund (GFF) - EIF Growth Facility
INAF – French National Agricultural Initiative
ESIF Energy Efficiency and Renewable Energy Malta
Regional Fund-of-Funds Romania
ESIF Fund-of-Funds Czech Republic
The Silesia EIF Fund of Funds
La Financière Région Réunion
The EIB Group Risk Enhancement Mandate (EREM)
Greater Anatolia Guarantee Facility (GAGF)
G43 - Anatolian Venture Capital Fund Project
InvestBG Equity Instrument
Romania Recovery Equity Fund of Funds
JEREMIE Romania Reflows – Equity Instrument
Luxembourg Future Fund (LFF)
Mezzanine 'Fund of Fund' for Germany (MDD)
Polish Growth Fund of Funds (PGFF)
Portugal Venture Capital Initiative (PVCi)
Scottish-European Growth Co-Investment Programme
Slovene Equity Growth Investment Programme (SEGIP)
Swedish Venture Initiative (SVI)
Turkish Growth and Innovation Fund (TGIF)
Western Balkans Enterprise Development & Innovation Facility (WB EDIF)
EAFRD FoF Greece
Irish Innovation Seed Fund (IISF)

Echolight: the new gold standard in the diagnosis of osteoporosis?


Osteoporosis is a systemic skeletal disease characterized by low bone mass and the deterioration of bone tissue, leading to increased fragility and fracture risk. While the debilitating effect can be prevented with early detection and effective treatments are available today, the disease is widely under-diagnosed and diagnosed late.

Founded in 2010, Echolight is a medical technology company that aims to change that situation. Echolight has developed the REMS (Radiofrequency Echographic Multi Spectrometry) technique, an innovative, patented solution for the diagnosis of osteoporosis at an early stage, through radiation-free echographic examination. The innovative test can provide an evaluation of bone strength in less than five minutes. It also offers a monitoring solution for osteoporosis that is non-ionizing, cost-effective, reliable, accurate and most importantly perhaps, more easily accessible, thus reducing waiting times. The implications for both patients and the healthcare budgets could be quite significant.

Headquartered in Lecce, Puglia, Echolight is led by a team with over 250 years of cumulative experience in the medical field. Their ambition is to become the new gold standard in the osteoporosis diagnostic market. “The technology currently used is dated,” explains Sergio Casciaro, CEO of Echolight, “but becoming the gold standard takes time. Research, clinical studies, certification, patenting…it is not an overnight process. But our results are very encouraging and we are confident about the future. Ultimately, we aim to improve the quality of life of patients, and that is something very motivating.”

In 2016, the company sought investment to support the clinical validation of this innovative technology and also to invest in marketing and lowering production costs. Panakés, an EIF backed venture capital fund that specialises in medical companies, invested in Echolight’s future. “The investment allowed us to hire a number of scientists to carry out clinical studies in 15 different hospitals across Europe” Sergio adds.

Fabrizio Landi, Managing Partner at Panakés, explains that they immediately recognized in Echolight “the right ingredients to be the winner in the osteoporosis diagnostic market. Their technology can overtake the current diagnostic method limitations such as x-ray exposure and low accuracy, making possible effective screening for this widely under-diagnosed pathology. Early detection is key in prevention.”

Company: Echolight (Italy)

Type of business: Medical devices

EIF financing:  COSME EFG

Financial intermediary: Panakés

For further information about EIF intermediaries in Italy please refer to: http://www.eif.org/what_we_do/where/it


We use cookies to give the best browser experience on our website. or change cookie settings.

Note: Following the recent withdrawal of the United Kingdom from the European Union, we are updating the relevant EIF.org pages.


Copyright ©

 European Investment Fund   – The European Investment Fund is not responsible for the content of external internet sites.